Prospective evaluation of the clinical profile and referral pattern differences of vestibular schwannomas and other cerebellopontine angle tumors.

OBJECTIVE: To evaluate the clinical profile, referral pattern, delay in diagnosis, and impact of tumor size of cases involving vestibular schwannomas (VS) versus other cerebellopontine angle (CPA) tumors in an Egyptian population. STUDY DESIGN: Case series study. SETTING: Tertiary referral center. PATIENTS: A prospective study of possible retrocochlear lesions was conducted from 2008 to 2010. INTERVENTION(S): Patients were subjected to a full clinical history, complete otorhinolaryngological examination, a basic audiologic evaluation, auditory brainstem response assay, and gadolinium-enhanced magnetic resonance imaging. According to the findings of magnetic resonance imaging, patients with retrocochlear lesions were divided into 2 groups: those with VS (n = 17) and those with other CPA lesions (n = 14). MAIN OUTCOME MEASURE(S): Diagnostic delay and criteria of VS and CPA tumors. RESULTS: Unilateral hearing loss and tinnitus were presented in 52.9% of VS cases with a diagnostic delay of 15.5 months. For cases involving other CPA lesions, a combination of otologic symptoms was observed in 9 (64%) of 14 cases, and a diagnostic delay of 47.5 months was experienced. An absence of auditory brainstem response waves was identified significantly (p < 0.05) for the affected ears of both groups. Only differences in Wave V latency were significant between the 2 groups (p < 0.05). CONCLUSION: A longer diagnostic delay was associated with cases involving other types of CPA lesions versus cases of VS, and tumor size and volume did not affect the diagnostic delay of the former. Moreover, the only significant difference in clinical presentation for these 2 groups of intracranial tumor involved Wave V latency.

Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT.

BACKGROUND: Malignant breast lesions usually are differentiated by FDG-PET with a semiquantitative FDG standardized uptake value (SUV) of 2.5. However, the frequency of breast cancer with an SUV of less than or equal to 2.5 is noteworthy, and often present diagnostic challenges. This study was undertaken to evaluate the accuracy of dual-time point FDG-PET/CT with FDG standardized uptake value (SUV) calculation in the characterization of such breast tumors. METHODS: Forty-nine female patients with newly diagnosed breast cancer were found to have primary breast cancer with minimally increased FDG uptake and met the criteria for inclusion in this study by having borderline levels of increased FDG uptake (SUV max less than or equal to 2.5) in the initial FDG-PET/CT images. Consequently, they underwent further delayed phase FDG-PET/CT scan for better evaluation of the disease. RESULTS: Of the 49 cancer lesions; the majority were found to have rising or unvarying dual-time changes in SUV max (75.5%). The median value of SUV max increases by 25% between the early and delayed scan. The means+/-S.D. of the SUV max1, the SUV max2, and the Delta SUV max% were 1.2+/-0.6%, 1.3+/-0.9%, and 5.1+/-22.4%, respectively. The receiver-operating-characteristic (ROC) analysis proved that the highest accuracy for characterization of malignant breast lesions was obtained when a Delta SUV max% cut-off value 0.0% was used as criteria for malignant FDG uptake-change over time with sensitivity 75.5%, and false-positive rate 20.4%. CONCLUSION: These results suggested that dual-time FDG-PET/CT imaging with standardized uptake value (SUV) estimation can improve the accuracy of the test in the evaluation of breast cancer with low FDG uptake.

Positron emission tomography and breast lesions: low FDG activity in early phase imaging is not essentially benign.

The frequency of malignancy with low FDG uptake is significant and often presents diagnostic challenges. The usefulness of dual-time point FDG-PET/CT imaging (including early "after 45 minutes" and delayed "after 100 minutes," phases after radionuclide administration) for detection of such tumors has been documented. The authors present 2 cases of pathologically proven breast cancer with minimally increased FDG uptake on the initial scan (maximum standardized uptake value; SUVmax <2.5). Detection was improved by performing a dynamic PET study with early and delayed scans. Patients with a poorly visualized breast lesion due to minimal FDG uptake on the initial FDG-PET images should not be considered as benign and deserves further delayed phase imaging.

Scarf pins sharp metallic tracheobronchial foreign bodies: presentation and management.

OBJECTIVES: Scarf pin inhalation is a cultural hazard in the Middle East young girls. So the aim of this work is to study the presentation of inhaled sharp airway foreign bodies (AFB) and its management. METHODS: Clinical and radiological presentation of inhaled sharp AFB was studied prospectively in 20 young females. All the sharp pins was extracted using rigid bronchoscopes with grasping forceps in 11 and magnetic extractor in 9. RESULTS: The most common presentation after inhalation was penetration syndrome (70%) (sudden onset of chocking and intractable cough). The distribution of AFBs was more significantly in the proximal 90% than the distal (p<0.05). It was significantly more in the left side (65%) than in the right side bronchial tree (5%) (p<0.05). The delay in diagnosis ranged from 6h to 1 week, with no complications on extraction. CONCLUSION: Scarf pins aspiration in females can be mainly presented with penetration syndrome. The site at presentation is mainly in left main bronchus. Early intervention, using rigid bronchoscopes with extraction using grasping forceps or magnetic extractor allowed easy and safe removal. Careful handling of these potentially sharp objects away from the mouth can prevent this critical problem.

Hepatocellular-cholangiocarcinoma: helical computed tomography findings in 30 patients.

OBJECTIVE: To report the helical multiphasic computed tomography (CT) findings in 30 patients with hepatocellular-cholangiocarcinoma. METHOD: We evaluated age, gender, tumor risk factors, serum tumor markers, symptoms, and tumor morphology and enhancement on helical multiphasic CT in 30 patients. RESULTS: Twenty-six of 30 patients (86%) were men. Patients had an age range of 27-78 years (mean = 58 years). Abdominal signs or symptoms were present in 21 of 30 patients, and 25 of 30 (83%) had chronic liver disease. Helical CT demonstrated a well-defined tumor in all patients with signs of malignancy such as hepatic hypervascularity (63%), biliary obstruction (17%), satellite lesions (40%), and lymphadenopathy (27%). Portions of the tumor were hyperattenuated on arterial-phase imaging and hypoattenuated on all other phases, whereas other portions showed delayed persistent enhancement, sometimes (27%) with hepatic capsular retraction, findings that have been reported to be characteristic of hepatocellular carcinoma and cholangiocarcinoma, respectively. CONCLUSION: The diagnosis of hepatocellular-cholangiocarcinoma should be considered when a hepatic tumor has CT features of both hepatocellular carcinoma and cholangiocarcinoma. Radiologists should be aware of this tumor type so that the biopsy is performed properly to allow sufficient tissue sampling.

Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma.

BACKGROUND: The authors used computed tomography (CT) scans to correlate the changes in tumor vascularity, necrosis, and size with response and survival after transcatheter arterial chemoembolization (TACE) in patients with advanced, unresectable, hepatocellular carcinoma (HCC). METHODS: The authors studied 72 patients with biopsy-proven, unresectable HCC and focused on 186 individual tumor masses. A baseline, multiphase, helical CT was performed and at least three follow-up CT scans were performed after treatment by TACE. Tumors were classified as hypervascular or hypovascular and patients were classified as responders or nonresponders based on CT evidence of altered tumor size, tumor necrosis, and the appearance of new tumors. A new scoring system was used to monitor patient response to TACE. RESULTS: Thirty-eight patients were responders and 34 were nonresponders. Patient survival was significantly increased (P = 0.009) in patients who were hypervascular responders. Survival also was increased in hypervascular nonresponders compared with hypovascular nonresponders (P = 0.008) and in hypovascular responders compared with hypovascular nonresponders (P = 0.002). Response to chemoembolization was found to be significantly (P = 0.02) and inversely proportional to tumor size, but the number of tumor foci in an individual patient was not predictive. CONCLUSIONS: TACE appears to result in improved survival among HCC patients with hypervascular tumors who responded to therapy. However, even patients classified by CT as hypervascular nonresponders and hypovascular responders have improved survival.